



Minutes

**FH & MCW Institutional Biosafety Committee
Institutional Biosafety Committee
12/9/2025
1:00 pm
Zoom**

1 **Statements of Confidentiality and Conflicts of Interest**

Quorum and Meeting Access: The Chair called the meeting to order at 1:01 pm and noted that the meeting was open to the public. Quorum existed at the start of the meeting with 12 voting members present. A quorum was maintained for the entire meeting.

Confidentiality: The Chair reminded the committee that while the meeting is open to the public, the information discussed during the meeting should be treated as confidential.

Conflict of Interest: The Chair asked the committee if any members needed to declare a conflict of interest with respect to any matter on the agenda. The Chair notified committee members that if they had a conflict of interest, they must leave the room during the final discussion and voting on that IBC submission.

2 **Attendees**

Committee Members Present

Lewis Bowen (Campus Operations)	Biological Safety Officer
Lezi E (Cell Biology Neurobiology and Anatomy)	R/SNA Technology Expert
Benjamin Gantner (Medicine)	Chair
Kunal Gupta (Neurosurgery)	R/SNA Technology Expert
Anna Huppler (Pediatrics)	R/SNA Technology Expert
Eric Jensen (Research Office)	Animal Containment Expert
Tyce Kearl (Medicine)	HGT Expert
	R/SNA Technology Expert
Nikki Lytle (Surgery)	R/SNA Technology Expert
Angela Mathison (Surgery)	R/SNA Technology Expert
Sandy Montes-Gruber (Non-MCW)	Non-Affiliated Member
Laura Stephens (Non-MCW)	Non-Affiliated Member
Matthew Surdel (Medicine)	R/SNA Technology Expert
Mindy Waggoner (Non-MCW)	HGT Expert

Committee Members Absent

Kenneth Allen (Research Office)

Alternate Animal Containment
Expert, Non-Voting

James Case (Non-MCW)

Non-Affiliated Member

Qizhen Shi (Pediatrics)

R/SNA Technology Expert

3 Meeting Minutes Reviewed at this Meeting

11/11/2025 (Zoom)

Motion:	Minutes Approved
Yes Votes:	13
No Votes:	0
Abstained:	0
Recused:	0
Total Votes:	13

4 New Business

The first and second business items were discussed before the past Meeting Minutes and Administrative Report were reviewed.

1. IBC Standard: *Review of IBC Applications*

The Chair presented the updated Institutional Biosafety Committee (IBC) Standard: *Review of IBC Applications* to the Committee. The updated Standard includes clarification that while all new IBC Applications and renewals are to be reviewed in their entirety, the focus of amendment review should be on the changes that have been made in the IBC Application, as discussed at the November 11, 2025 IBC Meeting. A Committee member asked if amendment reviews should also include sections of the IBC Application that may not have been updated by the Principal Investigator in the submitted amendment but are affected by recently approved or updated IBC Position Statements or have issues that may have been missed in the original approval. The Chair explained that such issues will be identified when applications are reviewed at the time of renewal, so unless the changes made in the current amendment affect the safety of previously approved materials, Committee members should focus on the changes that were made in the amendment. . A Committee member noted she recently reviewed an amendment which added more to the application than was stated in the Amendment Summary, and asked how the reviewers should handle these situations. The Chair stated that reviewers should utilize functionality in eBridge that highlights where changes have been made in the SmartForm. If Committee members need assistance with this, they may contact the IBC Office. The reviewers should also request that the PI update the Amendment Summary to include all changes made. There being no further discussion, upon a motion duly made by a Committee member and seconded, the Committee voted to approve the updates to the IBC Standard.

2. 2026 IBC Meeting Dates

The Chair provided the Institutional Biosafety Committee the meeting dates for 2026.

(A Committee member joined the meeting at 1:30 pm. Quorum was maintained with 13 Committee members.)

3. Administrative Report

The Chair asked the Committee Members to review the Administrative Report and then invited discussion. No concerns were raised.

5 Application Reviews

IBC20220081_REN01 [ENGENE-EG-70-101-LEGEND](#)

Principal Investigator: Scott Johnson
Motion: Decision Pending Changes
Yes Votes: 13
No Votes: 0
Abstained: 0
Recused: 0
Total Votes: 13
NIH Guidelines: Section III-C-1, Section III-F-8 (C-I)
Biosafety Level(s): BSL1, BSL2

Deliberations:

The Chair introduced this renewal of an Institutional Biosafety Committee (IBC) application and the Primary Reviewer elaborated on the study. This IBC application supports a Phase 1/2 study evaluating the safety and efficacy of EG-70 (detaimogen voraplasimid). EG-70 is a nanoparticle containing a DNA plasmid drug packaged in a polymer. The drug is prepared by Investigational Drug Service Pharmacy (IDS) and given in the urology clinic by study physicians. The bladder is clamped for one hour then the study drug is voided into the toilet. Blood, urine, tissue are collected and shipped off-site for analysis. The Committee confirmed that all personnel listed in the application completed safety training appropriate for work with the materials described. The Primary and Secondary Reviewers stated that the risk assessment and mitigation strategies are well described and appropriate. The Reviewers requested that the Principal Investigator (PI) update the location where EG-70 is prepared. The Biological Safety Officer (BSO) had no additional concerns. Upon a motion duly made by the Primary Reviewer and seconded, the Committee voted to approve this renewal application pending the requested change.

6 Adjournment

There being no further business, the meeting was adjourned at 2:09 pm. The next regularly scheduled meeting will be held on Tuesday, January 13, 2026 at 1:00 pm in Zoom.